Journal
VACCINE
Volume 23, Issue 7, Pages 857-864Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.08.020
Keywords
malaria vaccine; ICC-1132; sporozoite challenge
Categories
Funding
- Medical Research Council [G84/6323] Funding Source: researchfish
- MRC [G84/6323] Funding Source: UKRI
- Medical Research Council [G84/6323] Funding Source: Medline
Ask authors/readers for more resources
ICC-1132, a recombinant virus-like particle comprising of a modified hepatitis B core protein with a B cell (NANP) and two T cell epitopes of Plasmodium falciparum circumsporozoite protein (CSP), was administered i.m. as a single 50 mug dose in Seppic ISA 720 to 11 volunteers. Local reactogenicity and systemic side effects were acceptable with the predominant finding being mild pain at the injection site. This regimen induced anti-NANP antibodies in 10/11 and modest T cell responses. There was no evidence of protection from experimental challenge with P falciparum sporozoites. Other formulations and/or multi-dose regimens will be required to enhance the immunogenicity and efficacy of ICC-1132. (C) 2004 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available